Lenses linked to increased inflammatory markers

Article

Tear levels of inflammatory markers increase in patients who wear corneal refractive therapy lenses, compared to those who wore silicone-hydrogel lenses or no lenses.

Tear levels of inflammatory markers increase in patients who wear corneal refractive therapy lenses, compared to those who wore silicone-hydrogel lenses or no lenses.

A team led by Dr Javier González-Pérez, Ocular Surface and Contact Lens Research Laboratory, Faculty of Optics and Optometry, University of Santiago de Compostela, Spain, compared 60 participants in a prospective, case-controlled study.

Of the subjects studied, 28 wore a silicone-hydrogel lens continuously for 30 nights and 32 wore a corneal refractive therapy lens on an overnight basis. There were also 32 control subjects included in the investigation.

Twelve months after initial lens fitting tear samples were obtained and assayed using ELISA cytokines IL-6 andIL-8, matrix metalloproteinase 9 (MMP-9) and epidermal growth factor (EGF).

EGF significantly rose after 12 months for both lenses and IL-6, IL-8 and MMP-9 only increased after corneal refractive therapy. Inflammatory response for corneal refractive therapy patients was linked to the degree of myopia and the presence of corneal staining.

An increased level of MMP-9 and EGF was associated with the presence of corneal-pigmented arch in those who wore corneal refractive therapy lenses.,/p>

The abstract was recently published in the British Journal of Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.